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Abstract: Benzodiazepines are an important class of drugs commonly administered with a 
potential for abuse and environmental pollution.  This review focuses on the liquid 
chromatographic electrochemical detection of the benzodiazepine class of drugs.  These are 
characterised by a readily electrochemically reducible azomethine group, with a number 
also substituted by other electrochemically active groups.  Liquid chromatography 
employing both single and dual electrode detection has been reported for a variety of 
benzodiazepines and their metabolites in biological, pharmaceutical, biomedical and 
forensic investigations.  Recently, electrochemistry has been utilised to mimic biological 
oxidation processes and has been combined with liquid chromatography/mass spectroscopy 
for their identification and quantification of the products generated.  The present review 
focuses on recent developments in liquid chromatographic- electrochemical determination 
of benzodiazepines reported since 2006, with earlier reports given in summary. 
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1. Introduction:  
Since the discovery in 1955 of the first benzodiazepine drug, chlordiazepoxide hydrochloride 
(Librium
®
) [1], a number of structurally similar benzodiazepines have been synthesised, with about 
thirty presently in medical use [2].  These are utilised widely as tranquillisers, hypnotics, sedatives, 
antidepressants, for both humans [2-4] and animals [5], which act by increasing the efficiency of the 
neurotransmitter γ-aminobutyric acid (GABA) to decrease the communication between neurons, so 
calming many of the functions of the brain [2,3].  
Many of the pharmaceutically active benzodiazepines are based on the 1,4-benzodiazepine structure 
shown in Figure 1.  Here benzodiazepine refers to the portion of the structure composed of a benzene 
ring A fused to the seven-membered diazepine ring, B.  The majority also have an aryl substituent ring 
C.  The three ring systems are required for the benzodiazepine pharmaceutical activity [6].  The 
addition of an electron withdrawing group (i.e. Cl or NO2) at the 7 position is optimal for 
pharmaceutical activity with substitutions at other positions of this ring decreasing activity.  The other 
aryl ring system C contributes to benzodiazepine-receptor binding through hydrophobic and steric 
interactions.  Again, the type and position of substitutions in this ring affects the activity; an electron 
withdrawing group at the 2’ position increases the benzodiazepine activity, with substitutions at the 4’ 
position decreasing the activity.  The diazepine ring system B is required for optimum receptor 
binding; the amide or N-alkyl groups contribute to receptor binding, with biological activity increased 
by the addition of a methyl group at the 1-position, larger groups, such as tert-butyl result in decrease 
activity [6].   
There are a number of other structures based on dibenzo substituted forms, such as, clozapine, an 
antipsychotic during used in the treatment of schizophrenia and bipolar disorder and nevirapine, a 
reverse-transcriptase inhibitors, an antiretroviral drug used to treat HIV infection.  The ability to 
readily change the mode and activity of this class of drugs has made them a popular area of 
pharmaceutical development. 
Figure 1. 1,4-benzodiazepine ring systems.   
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However, for some time there has been a degree of controversy regarding the use of 
benzodiazepines [2,3,7,8] as prolonged use can result in increased tolerance, physical dependence and 
withdrawal symptoms; in addition overdoses result in symptoms such as respiratory depression or 
coma.  Reviews [9,10] have highlighted other issues, especially with the elderly, with increased reports 
of falls and a resulting increased incidence of hip fractures and risk of cerebrovascular events and 
deaths.   
Due to their wide pharmaceutical applications, and subsequent disposal, concern has also arisen 
regarding other areas effecting the wider population.  Reports have highlighted their use in drug-
facilitated crime (DFC), drug-facilitated sexual assaults (DFSA) [11-13] and abuse [2,8].  Detectable 
levels have also been recently reported in potable and environmental water systems, resulting in 
possible toxic effects for both humans and aquatic life [14-16].  Consequently, there is a pressing 
demand for methods capable of determining trace levels of benzodiazepines in both environmental and 
medical biological samples.  Common analytical approaches utilised for the determination of 
benzodiazepines, such as, gas chromatography [17], immunoassay [17-19], liquid chromatography 
[19-21] and spectroscopy [22] have been reported.  However, the application of liquid chromatography 
with electrochemical detection for the analysis of this group of drugs has not been recently reviewed.  
In this article we review such developments since 2006. 
2. The Electrochemical Behaviour of Benzodiazepines  
The 1,4-benzodiazepine class of drugs are characterised by a relatively easily reducible azomethine 
group; a number also contain other electrochemically active groups such as, nitro, N-oxide and 
carbonyl groups.  The 2e
-
, 2H
+
 electrochemical reduction of the azomethine group results in the 
corresponding dihydro derivative (eq. 1) [23].   
 
R-C=N-R’ + 2e- + 2H+   →  R-(H)C-N(H)-R’        (eq.1) 
Many of the 1,5-benzodiazepines, such as clobazam are reported to be electrochemically inactive 
[24].  However, some, such as the 3H-1,5-benzodiazepines [25] have been shown to undergo two 2e
-
, 
2H
+
 reductions at their azomethine groups.  The dibenzo substituted benzodiazepines such as clozapine 
(scheme I) undergo a reversible 2e
-
, H
+
 redox reaction involving a relatively stable nitrenium ion 
[26,27]. 
Scheme I 
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Benzodiazepines 
Determined 
Mobile and stationary 
phase 
Linear range Detection 
limit 
Electrode Sample Ref. 
Bromazepam, 
Lorazepam, 
Nitrazepam, 
Clonazepam, 
Nordiazepam, 
Flunitrazepam, 
Diazepam, 
Temazepam, 
Midazolam 
0.02 M phosphate 
buffer (pH 6) and 
acetonitrile 55:45 
(v/v). LiChrospher-
100 RP-8ec column 
(150 x 4.6 mm). 
Up to at least 2 
mg/l for each 
compound. 
In the range 
of 6.5–123 
ng/ml (130 
pg–2.46 ng 
on-column) 
hanging mercury drop 
electrode at -1.4 V (vs. 
Ag/AgCl), coupled with 
UV detection at 250 nm 
Forensic human 
blood samples, 
following liquid –
liquid extraction 
with CHCl3 
[31] 
Clonazepam, 
Diazepam, 
Flunitrazepam, 
Lorazepam, 
Nitrazepam, 
Nordiazepam, 
Flurazepam, 
Oxazepam 
0.03 M pH 4.6 acetate 
buffer and acetonitrile 
55:45 (v/v). 
LiChrospher-100 RP-
8ec(150 x 4.6 mm) 
25 – 200 µg/l 
utilising N-
methylclonazep
am as internal 
standard 
2.0 to 4.1 
ng/ml 
hanging mercury drop 
electrode at -1.4 V (vs. 
Ag/AgCl), coupled with 
UV detection at 250 nm 
Forensic human 
blood, plasma, 
urine and saliva 
samples, 
following liquid –
liquid extraction 
with CHCl3 
[32] 
7-
acetamidonitrazepam, 
7-aminonitrazeapam, 
chlordiazepoxide, 
demoxepam, 
desmethylchlordiazepo
xide, 
desmethyldiazepam, 
diazepam, lorazepam, 
Loprazolam, 
nitrazepam, oxazepam, 
temazepam, triazolam 
Methanol-1-propanol-
aqueous pH 6.0 
phosphate buffer 
(100:7:5:80).  CPS-
Hypersil column (100 
x 4.5 mm) 
Nitrazepam 4.2 
– 1070 ng/ml, 7-
acetamidonitraz
epam and 7-
aminonitrazeapa
m, 16.7 – 2140 
ng/ml.  All 
others 8.4 – 
2140 ng/ml 
Range 
between 1–5 
ng/ml (40–
200 pg 
injected) 
pendent mercury drop 
electrode at -1.2 V, 
preceded by a coulometric 
detector fitted with porous 
carbon electrodes held at 0 
V 
Blood, diluted 
with aqueous 
sodium octyl 
sulphate to 
suppress protein 
binding, followed 
by microcolumn 
clean-up 
[60] 
Nitrazepam, diazepam, 
chlordiazepoxide 
Methanol-water 
(60:40) containing 
0.05 M ammonium 
acetate, 1.0 ml/min. 5 
µm Spherisob ODS 
(250 x 2.6 mm) 
Nitrazepam, 7 to 
1400 µg/ml 
Nitrazepam 3 
ng at -0.93 V.  
Diazepam and 
chlordiazepox
ide not 
detected.  30 
ng for 
nitrazepam 
and 300 ng 
for both 
diazepam and 
chlordiazepox
ide at -1.30 V. 
Amperometric detector, 3 
mm diameter glassy 
carbon electrode in a wall-
jet configuration 
- [61] 
Chlordiazepoxide and 
N-desmethyl-
chlordiazepoxide 
Methanol- 
isopropanol-7.5 mM 
acetate buffer pH 3.5 
(53:5:42), at a flow 
rate of 0.9 ml/min.  
300 x 3.9 mm 10 µm 
µBondapak C18 
column 
0.05 – 2.0 µg/ml 
for plasma, 
utilising 
medazepam as 
an internal 
standard 
5.0 ng Differential pulse mode, 
-0.820 V at a dropping 
mercury electrode. 
Plasma adjusted to 
pH 9, extracted 
with diethyl ether, 
reconstituted in 
isopropanol 
[62] 
Oxazepam, Lorazepam 
and Chlordiazepoxide 
Partisil ODS-3, 110 x 
4.7 mm, 5 µm column.  
0.1 M ammonium 
acetate-acetonitrile 
(60:40 v/v) at a flow 
rate of 1.3 ml/min. 
Qualitative.  
Ratio between 
peak obtained at 
+1.1 V at and 
that obtained at 
+1.0 V by 
parallel dual 
electrode 
detection. 
Qualitative Parallel dual electrode 
detection (+1.1 V, +1.0 V) 
as part of diode array, 
thermospray mass 
spectrometry detection 
system. 
Quantification 
made by diode 
array and mass 
spectroscopy, of 
chlorazepate, 
Bromazepam, 
Demoxepam, 
Nitrazepam, 
Clonazepam, 
Alprazolam, 
Triazolam, 
Desalkylflurazepa
m, Nordiazepam, 
Temazepam, 
Flunitrazepam, 
Diazepam, 
Midazolam, 
Tetrazepam, 
Prazepam, 
[63] 
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Halazepam, 
Medazepam, 
Oxazepam, 
Lorazepam and 
Chlordiazepoxide. 
Olanzapine 150 x 4.6 mm, 5 µm 
YMC basic column, 
mobile phase of 75 
mM sodium phosphate 
(pH 7)-methanol-
acetonitrile (48:26:26), 
a flow-rate of 1.2 
ml/min, and a column 
temperature of 40°C. 
0.25 – 100 
ng/ml 
0.25 ng/ml ESA Coulochem model 
5100A electrochemical 
detector with a Model 
5011 electrode cell. The 
electrochemical detector 
guard cell was set at +0.3 
V and the analytical cell 1 
+0.2 V, cell 2 -0.2 V. 
Human plasma, 
following solid 
phase extraction 
[64] 
Olanzapine 250 x 4.6 mm, 5 µm, 
Ultrasphere Cyano 
column, mobile phase 
130 mM ammonium 
acetate pH (6.8 not 
adjusted), methanol, 
acetonitrile (8:6:86) 
0.25 – 50 ng/ml 
(using 2-
methylolanzapin
e as internal 
standard). 
0.25 ng/ml 
plasma 
ESA Coulochem model 
5100A electrochemical 
detector; guard cell set at 
+1.0 V (between pump 
and injector), the 
analytical cell 1 set at +0.3 
V, cell 2 +0.93 V. 
Human plasma, 
following 
extraction with 15 
% 
dichloromethane 
in pentane 
[65] 
Olanzapine and 
desmethylolanzapine 
C8, 150 x 4.6 mm, 5 
µm using acetonitrile–
phosphate buffer, 15.4 
mM pH 3.8, 
containing 19.7 mM 
triethylamine (20/80) 
as the mobile phase, 
flow-rate 1.2 ml/min 
5–150 ng/ml for 
both 
1 ng/ml for 
both 
Amperometric detector, 
glassy carbon electrode, 
+800 mV 
human plasma [66] 
Olanzapine YMC basic column 
(150 mm x 4.6 mm, 5 
µm) at a flow-rate of 1 
ml /min, 75 mM 
phosphate buffer, pH 
7.0–acetonitrile–
methanol (48:26:26, 
v/v/v) mobile phase. 
0.25–100 ng/ ml 0.25 ng/ml ESA Coulochem Model 
5200A electrochemical 
detector with a model 
5011 electrode cell. 
Electrochemical detector 
guard cell was set at -0.3 
V and the analytical cell 1 
-0.2 V, cell 2, +0.2 V. 
human breast 
milk, following 
solid phase 
extraction 
[67] 
Olanzapine YMC Basic HPLC 
column (5 µm, 150 x 
4.6 mm, 75 mM pH 
7.0 phosphate buffer- 
methanol–acetonitrile 
(48:26:26, v/v/v), 1.2 
ml/min 
0.5–100 ng/ml 0.5 ng/ml ESA Coulochem Model 
5100A electrochemical 
detector with a model 
5011 with a dual analytical 
cell. Cell 1 -0.2 V, cell 2 
+0.2 V, Model 5010 guard 
cell, -0.3 V. 
rat brain tissue, 
after liquid 
extraction with 
15% 
dichloromethane  
in cyclohexane 
[68] 
Nitrazepam and 
clonazepam 
LiChrosorb RP-18 250 
x 4.0 mm 5 µm. 0.1 M 
potassium nitrate-0.02 
M sulphuric 
acid/methanol (50/50 
% v/v 1.0) 1.0 ml/min 
- - Static mercury drop 
electrode-0.85 V 
- [69] 
Nitrazepam ODS hypersil (5 µm 
100 mm x 4.6 mm).  
1.0 ml/min water-
methanol, 50/50 % v/v 
0.1 M KNO3, 10
-3 M 
HNO3 
10-4- 4x10-8 M 0.7 pM Dropping mercury 
electrode 
bromazepam and 
diazepam also 
shown 
[70] 
Clotiazepam Bondpak C18 300 x 3.9 
mm. Methanol-water 
(70:30) containing 
0.01 M acetate buffer 
pH 4.  Flunitrazepam 
as internal standard. 
- 2.5 µg on 
column 
Glassy carbon electrode, 
amperometric 
Tablets [71] 
Olanzapine, N-
desmethyl and 2-
hydroxymethyl 
metabolites 
75 mM phosphate 
buffer, adjusted to pH 
7 with 5 mM NaOH, 
acetonitrile and 
methanol (48/26/26 
v/v/v).  YMC basic 
column, 150 x 4.6 
mm, 5 µm. 
1-100 ng/ml, 
using 
LY170222 (2-
methylolanzapin
e) as internal 
standard 
1 ng/ml after 
solid-phase 
extraction 
(Bond Elute 
LRC 
cartridges) 
ESA Coulochem II (Model 
5200) electrochemical 
detector with a model 
5010 dual analytical 
detector. Cell 1 -0.2 V, cell 
2 +0.2 V, Model 5010 
guard cell, -0.3 V. 
Rat plasma [72] 
Clozapine, N-
desmethylclozapine, 
ODS-3 column, 
methanol and 0.1 M 
- - +0.6, +0.6 and +0.35 V at 
pH 4.56 and +0.48, +0.48 
- [73] 
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 Table 1. Pre-2006 applications of liquid chromatography coupled with electrochemical detection for 
the determination of benzodiazepines 
 
 
These redox processes have been shown to occur with a variety of electrode materials and as a 
result a range of different electrochemical techniques, including polarography and voltammetry have 
been successfully utilised.  These have been shown to be sensitive, economic and flexible and have 
been exploited for the determination of a range of parent benzodiazepines and their metabolites in 
complicated matrices such as blood [28-30], and forensic samples [31-34].  Utilising techniques such 
as adsorptive stripping voltammetry [35] detection limits in the nM to µM range are readily obtainable.  
Some recent reports describe the application of ion selective electrodes [36-39] and electrochemical 
biosensors [40,41] for the determination of benzodiazepines.  Electrochemical detection can be readily 
employed with flow injection analysis and liquid chromatography employing both single and dual 
electrode detection systems.  Recent studies have illustrated the possibility of using electrochemistry to 
simulate drug metabolism and has been coupled to mass spectroscopy for product identification.  
This review focuses on liquid chromatography coupled with electrochemically based techniques for 
the determination of the benzodiazepine class of drugs.  Liquid chromatographic approaches using 
both single and dual electrode detection are included as well as electrochemical derivatisation in 
conjugation with mass spectroscopy.  Details of methodology, design and performance of selected 
olanzapine and 
olanzapine 
phosphate pH 4.56 or 
pH 5.56 buffer (60:40 
v/v) 
and +0.3 V at pH 5.56 for 
clozapine, N-
desmethylclozapine, 
olanzapine and olanzapine 
respectively 
Olanzapine Varian ResElut C8 150 
x 4.6 mm, 5 µm, 
acetonitrile –
phosphate buffer pH 
2.5 
2-100 ng/ml 1.4 ng/ml, 
solid-phase 
extraction C8 
Bond elute 
Glassy carbon electrode 
+0.900 V 
Human plasma [74] 
Olanzapine YMC basic column, 
150 x 4.6 mm, 5 µm. 
75 mM phosphate 
buffer/methanol/aceto
nitrile 48/26/26 (v/v/v) 
0.250-100 
ng/ml, using 
LY170222 (2-
methylolanzapin
e) as internal 
standard 
0.25 ng/ml 
limit of 
quantitation 
following 
automated 
solid phase 
extraction 
with Bond 
Elute Certify 
cartridges in a 
96-well plate 
formate 
Glassy carbon electrode, 
amperometric, potential 
not stated. 
Human plasma [75] 
Olanzapine C8 reversed phase 
column (150 mm×4.6 
mm, 5 µm), using a 
mobile phase 
composed of methanol 
and a phosphate buffer 
(44.0 mM, pH 3.5), 
containing 
triethylamine (21:79, 
v/v), flowing at 1.2 
ml/min 
0.2-100.0 ng/ml, 
using 
LY170222 (2-
methylolanzapin
e) as internal 
standard 
0.20 ng/ml 
limit of 
quantitation, 
solid-phase 
extraction 
Waters Oasis 
hydrophilic-
lipophilic 
balance 
cartridges. 
ESA Coulochem III 
(Model 5011) 
electrochemical detector 
with a dual analytical 
detector. Cell 1 +0.350 V, 
cell 2 -0.200 V. 
Rat brain [76] 
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applications are given and discussed for research papers published in the past seven years with reports 
made prior to 2006 being summarised in table 1.  A number of earlier investigations have already been 
reviewed [28, 42-46] 
3. Liquid Chromatography Electrochemical Detection of Benzodiazepines 
Many benzodiazepines are known to be thermal unstable and form common degradation products.  
As a result techniques such as liquid chromatography which can be undertaken at ambient or near 
ambient temperatures are popular methods for the separation and quantification of these drugs 
[21,47,48].  Recently, Trojanowicza has reviewed the utilisation of electrochemical detection with both 
flow injection analysis [49] and liquid chromatography [47] for a range of compounds.  The 
underlying theory and applications including the determination of several benzodiazepines was 
described [43,50-52].  Attention first focused on LC-ED with regard to neurochemical problems, 
leading to the first commercially available detectors being produced in 1974 [52].  These systems had 
several advantages including enhanced selectivity, low detection limits and low cost.   
Normal phase chromatography cannot generally be utilised as nonpolar solvents are not suitable for 
use with common buffers.  However, recent studies have shown the possibility of utilising related 
techniques such as hydrophilic interaction liquid chromatography with electrochemical detection [53]. 
 
4. Applications 
Table 1 gives a summary of the liquid chromatographic approaches that have been reported prior to 
2006.  A variety of different approaches has been described including coulometric and amperometric 
and dual electrode systems.  Both Hg and carbon based working electrodes have been employed 
successfully for benzodiazepine determination in complex samples such as blood, milk and tissue.  
More recently, Martins et al [54] have reported on the determination of diazepam, clonazepam, 
flunitrazepam and nitrazepam using boron doped diamond electrode (BDDE), as part of a liquid 
chromatographic system.  Cyclic voltammetry was employed to investigate the electrochemical 
behaviour of the four benzodiazepines at the BDDE in 0.1 M phosphate buffer at pH 3.5, 6.0 and 8.0 
with the optimum response obtained at pH 3.5.  Chromatographic separation was achieved using an 
octyldecyl stationary phase in conjugation with a mobile phase comprising sodium phosphate (pH 3.5; 
0.10 M) acetonitrile (65:35, v/v), at a flow rate of 1.2 ml/min.  A thin layer amperometric detector 
operated in the pulse mode was used for the detection of the benzodiazepines.  The optimum wave 
form for the reduction was reported to be -1.9 V, +1.5 V and -0.5 V, with repetition time of 0.5 s.  
Detection limits of 0.5, 0.6 and 2.0 µg/ml were reported for nitrazepam, clonazepam and diazepam 
respectively.  Analysis of pharmaceutical tablet formulations showed good agreement with that found 
by liquid chromatography with UV diode array detection. 
Liquid chromatography dual electrode detection (LC-DED) has been shown to be a powerful 
analytical technique and has been utilised for the determination of a number of benzodiazepines (table 
1).  Recently, LC-DED in the redox mode has recently been explored by Honeychurch et al [55] for 
the determination of nitrazepam in serum.  In this approach, two electrochemical cells are arranged in 
series after the analytical chromatographic column.  The first upstream cell is used as the “generator” 
cell to reduce nitrazepam to the corresponding hydroxylamine species, which is then detected at the 
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second downstream “detector” cell via oxidation to the corresponding nitroso species.  The advantage 
of this approach is that the electrochemically generated product is much more readily oxidized or 
reduced than the parent compound; consequently lower applied potentials are required for its 
determination, so allowing for improvements in selectivity of the system, as the detector potential is 
operated at a lower applied potential.  The sensitivity of the system is also improved as a result of the 
lower background currents occurring at the detector electrode compared with those obtained at the 
high potentials required for direct electrochemical detection.  This can be readily seen in figure 2, 
where chromatograms obtained for fixed 300 ng injections of nitrazepam using the reductive mode and 
DED mode detection techniques are shown.  As can be readily seen, the best signal-to-noise ratio was 
obtained by using the redox mode (figure 2b and 2c). Incidentally, it was found impossible to operate 
the detector at low nA ranges in the direct reductive mode, (figure 2a) due to excessive baseline drift; 
this probably arises from the ingress of oxygen into the mobile phase even though degassing was 
performed continuously.  In addition, an unresolved pre-peak was seen in the reductive mode (figure 
2a); this would result in significant errors when calculating nitrazepam levels in serum samples.  Such 
effects demonstrate the superior analytical responses that can be obtained using DED.  Using LC-
DED, nitrazepam levels in both human and bovine serum could be successfully determined following a 
simple, rapid sample preparation step.  A mean recovery of 74 % (%CV = 7.8 %) was obtained for a 
human serum sample fortified with 1670 ng/ml nitrazepam. 
More recently, a variation on this technique for the determination of both nitrazepam, and 
flunitrazepam, in beverage samples such as Pepsi Max
®
 has been reported by Honeychurch and Hart 
[56].  In this approach a carbon fibre veil electrode (CFVE) was incorporated as the generator 
electrode to increase the conversion efficiency of this flow cell.  Cyclic voltammetric studies were 
performed to ascertain the redox behaviour of nitrazepam and flunitrazepam at a CFVE in the 
optimised mobile phase.  As can be seen in figure 3, cyclic voltammetric behaviour of the two 
compounds was similar to that obtained with a GCE.   
Interestingly, a novel reduction-reduction LC-DED approach could be exploited to measure these 
two nitro containing drugs.  The initial reduction reaction occurring at the at the generator electrode 
was postulated to result from a two 2e
 
, 2H
+
 reduction of the 7-nitro group first to the corresponding 
nitroso species, with the associated loss of water.  This was then followed by a further 2e
-
, 2H
+
 
reduction at the detector electrode to the corresponding hydroxylamine.  A linear range of 2.0 to 100 
μg/ml, with a detection limit of 20 ng/ml was obtained.  Only a simple sample extraction procedure 
was required prior to analysis using the optimised LC-DED procedure. A mean recovery of 95.5% 
(%CV = 4.5%) for nitrazepam and 78.0% (%CV = 8.8%) was achieved for a beverage sample spiked 
at 1.0 μg/ml nitrazepam and 1.47 μg/ml flunitrazepam. 
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Figure 2. Chromatograms obtained for 300 ng of nitrazepam in (a) reductive mode and (b) and (c) 
redox mode. Detector currents ranges: 10 nA FSD for (a) and (b); 2 nA FSD for (c). Reprinted with 
permission from Honeychurch K.C., Smith G.C., Hart J.P., Voltammetric Behavior of Nitrazepam and 
Its Determination in Serum Using Liquid Chromatography with Redox Mode Dual-Electrode 
Detection, Anal. Chem. 2006, 78, 416-423. Copyright 2006 American Chemical Society. 
 
 
 
 
Saracino et al [57] have reported the application of high-performance liquid chromatography with 
both coulometric and diode array detection for the therapeutic drug monitoring of patients with bipolar 
disorders; the patients were treated with olanzapine and lamotrigine.  Chromatographic separation was 
achieved with a reversed-phase C8 column (150 x 4.6 mm, 5 µm) using a mobile phase composed of 
methanol (27%) and a 50.0 mM, pH 3.5 phosphate buffer (73%). For the analysis of olanzapine and its 
main metabolite, N-desmethylolanzapine, a dual coulometric detector was used, with the first 
downstream electrode 1 set at -200 mV and the subsequent upstream electrode 2 at +500 mV.  
Lamotrigine was determined using diode array detection at 220 nm with the two detectors connected in 
series.  For the analysis of biological samples, a clean-up procedure was implemented by means of 
solid-phase extraction using phenyl cartridges and eluting the analytes with methanol.  Recoveries 
greater than 90%, with an associated precisions of <3.4% were reported.  Linear responses were 
obtained between 0.1 and 50.0 ng/ml for olanzapine, 0.1 and 25.0 ng/ml for N-desmethylolanzapine, 
and between 0.25 and 10.0 µg/ml for lamotrigine.  The method was applied successfully to some 
human plasma samples drawn from bipolar patients undergoing combined therapy with the two drugs.  
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Figure 3. Cyclic voltammograms, for: (a) carbon fibre veil electrode (CFVE) 0.1 mM nitrazepam, (b) 
CFVE 0.1 mM flunitrazepam (c) GCE 1.0 mM nitrazepam and (d) GCE 1.0 mM flunitrazepam. i 
denotes the absence of and ii the presence of the benzodiazepine. Starting potential 0.0 V, initial 
switching potential −1.5 V, second switching potential +0.6 V at a scan rate of 100 mVs 1, in 45% 
acetonitrile–55% acetate buffer (50 mM, pH 4.1) J. Solid State Electr. 12, 2008 1317-1324, 
Determination of Flunitrazepam and Nitrazepam in Beverage Samples by Liquid Chromatography 
with Dual Electrode Detection Using a Carbon Fibre Veil Electrode, Honeychurch K.C., Hart J.P., 
with kind permission from Springer Science+Business Media B.V. 
 
 
 
 
 
In an alternative approach, Kobylińska et al [58] successfully utilised HPLC with amperometric 
detection at +0.6 V for the determination of olanzapine in human plasma with a glassy carbon working 
electrode, cleaned by pulsing the applied potential.  Blood was collected from volunteers and 
centrifuged at 3500 rpm the separated plasma was decanted and ascorbic acid was added to protect the 
olanzapine from oxidation.  The internal standard, clozapine was then added to 0.5 ml of the resulting 
plasma sample and after the addition of 0.25 ml of 40 mM sodium carbonate, extracted with 2 ml of 
ethyl acetate, by shaking for 5 minutes.  The two phases were separated by holding the sample/solvent 
mixture at -70 ºC for 10 minutes.  The resulting organic phase was then evaporated to dryness and 
reconstituted in a mixture of 200 µl of methanol and 200 µl of 0.06 M ammonium acetate.  This was 
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then mixed and introduced to the HPLC system.  Separations were achieved using a 125 x 4.0 mm, 5 
µm C18 column with a mobile phase of 0.06 M ammonium acetate buffer, pH 5.9, acetonitrile and 
methanol at flow rate of 0.69 ml/min.  The method was able to determine olanzapine plasma 
concentrations after the administration of one 10 mg oral dose over a period of 120 hours.  A linear 
response over the range 0.313-25.00 ng/ml was reported, the former being the limit of quantification.   
Recently, Honeychurch et al [59] successfully exploited a previously unreported electrochemical 
redox reaction for flunitrazepam, lorazepam and diazepam for their determination in serum by LC-
DED.  The initial cyclic voltammetric investigation represented the first report on the anodic behaviour 
of diazepam and lorazepam.  Previous reports had only recorded the reduction of the 4,5-azomethine 
group, with no further redox peaks reported.  However, in this study, new oxidation peaks were 
recorded which did not occur without prior reduction of the molecule.  These redox processes were 
investigated for the possible LC-DED determination.  Studies were performed to optimise the 
chromatographic conditions and were found to be 50 % acetone, 50 % 100 mM pH 2 phosphate buffer 
at a flow rate of 0.8 ml/min, employing a Hypersil C18, 5 µm, 250 mm x 4.6 mm column held at 40 °C 
using a generator potential of -2.4 V (vs. stainless steel) and detector potential of +1.0 V (vs. 
Ag/AgCl).  Enhancement in both peak height and peak area (coulombs) was seen with decreasing flow 
rate, probably resulting from improvements in the electrolytic conversion efficiency of the cell at lower 
flow rates. This decrease in flow rate results in a higher conversion of the analyte at the working 
electrode and consequently, larger peak areas (coulombs) are expected. Figure 4 shows the resulting 
chromatograms obtained under the optimised conditions for fortified and unfortified bovine serum. 
 
Figure 4.  Typical chromatogram obtained in the redox mode for bovine serum extracts. Solid line, 
fortified with lorazepam (16.0 mg/l), flunitrazepam (1.60 mg/l) and diazepam (14.2 mg/l), dotted line 
unadulterated.  Reproduced from Ref. [59] with permission from The Royal Society of Chemistry. 
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Figure 5.  Comparison of the oxidative metabolites of tetrazepam found in urine (6 h after Myolastan 
intake), in an incubation mixture with rat liver microsomes (RLMs) and in an electrochemical 
simulation (EC). Peak assignment: 1, tetrazepam- CH3 +O; 2, 3, 6–8, 10, tetrazepam +O; 4, 
tetrazepam-H2 +O; 5, tetrazepam-2H2 +O; 9, tetrazepam-2H2; 11, tetrazepam-CH3; 12, tetrazepam-H2; 
*Peaks which were also present in a Myolastan solution without electrochemical oxidation.  Reprinted 
from Journal of Chromatography A, 1216, 15, Baumann A., Lohmann W., Schubert B., Oberacher H., 
Karst U., Metabolic studies of tetrazepam based on electrochemical simulation in comparison to in 
vivo and in vitro methods, 3192-3198, Copyright (2009), with permission from Elsevier. 
 
 
 
 
5. Combined On-line Electrochemistry/ Mass Spectrometry Analysis  
Recently reports have shown the possibility of utilising on-line electrochemistry/mass spectrometry 
(EC/MS) as a rapid economic method for early-stage drug metabolite discovery and to anticipate 
biological oxidation patterns.  Baumann et al [77] have utilised LC-MS in series with an 
electrochemical wall-jet generator electrode to model the metabolic pathway of tetrazepam.  The 
electrochemical results were compared to results from microsomal incubations, and to those generated 
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by in vivo studies obtained with urine samples from a patient after tetrazepam delivery (Figure 5).  The 
tetrazepam sample was injected into the electrochemical wall-jet cell by syringe pump; the applied 
potential was +2.0 V.  The resulting electrochemically generated oxidation products were then 
separated and determined by LC-MS.  A number of metabolites were identified, including 
nortetrazepam and 3-hydroxytetrazepam and notably diazepam.  Earlier studies by Mouithys-Mickalad 
et al [78] and van Leeuwen [27] utilised a similar approach to study the metabolism of clozapine.  
These authors employed different applied potentials to a porous carbon electrode, and were able to 
generate a variety of hydroxylated and demethylated species.  Hydroxylated species were reported to 
be most abundant using a potential of +0.4 V, with demethylated species being produced at +0.7 V (vs. 
Pd/H2).  The addition of reduced glutathione was found to result in the formation of a number of 
isomeric glutathione adducts, reportedly similar to that described in the literature for phase I and II 
metabolism. 
6. Conclusion  
The benzodiazepines class of drugs have a long history of pharmaceutical usage and are still 
commonly used medically for a number of conditions.  However, reports have described their use in 
criminal activity and their contamination of the environment has now become now a more commonly 
reported problem.  The realisation that benzodiazepines are characterised by a facile electrochemically 
reducible azomethine group, with a number also containing other electro-active groups, such as, nitro, 
hydroxyl and N-oxide has resulted in their determination using electrochemical detection methods 
following HPLC with a range of different electrode materials.   
Applications for the liquid chromatographic electrochemical determination of 1,4-benzodiazepines 
have utilised both reductive and more recently dual electrode modes of detection.  Both approaches 
allow for low detection limits, and have been shown to be applicable for the determination complicated 
samples, such as serum and forensic samples.  However, the reductive mode has been shown to suffer 
from common interferences, such as oxygen.   
New analytical developments will continue to be made for other areas other than medical and 
pharmaceutical analysis, such as in forensic and environmental analysis and has already been shown 
for the simulation of drug metabolism.  The development of new benzodiazepines and related drugs, 
such as zaleplon and zolpidem will also drive the further developments of electrochemical assays for 
this important class of drugs. 
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